Literature DB >> 16677779

Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.

Hye-Rim Park1, Woon Won Jung, Patrizia Bacchini, Franco Bertoni, Youn-Wha Kim, Yong-Koo Park.   

Abstract

Ezrin is a cytoskeleton linker protein that is actively involved in the regulation of growth and metastatic capacity of cancer cells. Recently, it has been demonstrated that a significant correlation exists between high ezrin expression levels and the poor outcome of pediatric osteosarcoma patients. The expression of ezrin was compared in conventional high-grade and central low-grade osteosarcoma lesions to investigate the role of ezrin overexpression in the metastasis of osteosarcoma. We compared the expression levels of the ezrin protein in 32 cases of high-grade osteosarcomas and 21 cases of low-grade osteosarcomas using immunohistochemistry. Ezrin protein expression levels were examined in three different human osteosarcoma cell lines by Western blotting. In addition, the mRNA expression levels of ezrin in these osteosarcoma cell lines and control fibroblasts were evaluated by real-time quantitative PCR. Ezrin immunoreactivity was present in 43.7% of high-grade osteosarcoma specimens. All low-grade osteosarcomas were negative for ezrin. The expression of ezrin was detected by Western blotting in all three osteosarcoma cell lines. The tested osteosarcoma cell lines showed marked amplification of ezrin mRNA compared to control cells. Taken together, ezrin appears to play a role in the progression of tumors, such as the metastasis of osteosarcoma. However, further data are needed before ezrin can be considered in clinical decision-making about osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677779     DOI: 10.1016/j.prp.2006.01.015

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  23 in total

1.  Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro.

Authors:  Qing-Yong Chen; Wei Xu; De-Min Jiao; Li-Jun Wu; Jia Song; Jie Yan; Jian-Guo Shi
Journal:  Mol Cell Biochem       Date:  2013-02-22       Impact factor: 3.396

2.  MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin.

Authors:  Ce Zhan; Cheng Li; Hao Zhang; Hao Tang; Fang Ji; Su-Chi Qiao; Wei-Dong Xu; Zhi-Wei Wang
Journal:  Oncol Lett       Date:  2016-08-25       Impact factor: 2.967

3.  Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Authors:  G Bulut; S-H Hong; K Chen; E M Beauchamp; S Rahim; G W Kosturko; E Glasgow; S Dakshanamurthy; H-S Lee; I Daar; J A Toretsky; C Khanna; A Uren
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

Review 4.  Osteosarcoma metastasis: prospective role of ezrin.

Authors:  Yuanjin Zhang; Ling Zhang; Guofu Zhang; Songbai Li; Jun Duan; Jie Cheng; Guozhen Ding; Chibing Zhou; Jie Zhang; Pengcheng Luo; Dongbing Cai; Lianghong Kuang; Yichun Zhou; Liqun Tong; Xiangdong Yu; Lifang Zhang; Lijun Xu; Li Yu; Xiaomei Shi; Aihong Ke
Journal:  Tumour Biol       Date:  2014-03-09

Review 5.  Alteration of WWOX in human cancer: a clinical view.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Andrzej K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

6.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

7.  Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level.

Authors:  Haydar Çelik; Kamal P Sajwan; Saravana P Selvanathan; Benjamin J Marsh; Amrita V Pai; Yasemin Saygideger Kont; Jenny Han; Tsion Z Minas; Said Rahim; Hayriye Verda Erkizan; Jeffrey A Toretsky; Aykut Üren
Journal:  Mol Cell Biol       Date:  2015-07-06       Impact factor: 4.272

8.  Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.

Authors:  Sébastien Salas; Gonzague de Pinieux; Anne Gomez-Brouchet; Frédérique Larrousserie; Xavier Leroy; Sébastien Aubert; Anne-Valérie Decouvelaere; Roch Giorgi; Carla Fernandez; Corinne Bouvier
Journal:  Virchows Arch       Date:  2008-12-03       Impact factor: 4.064

9.  The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults.

Authors:  Iwona Lugowska; Ewa Mierzejewska; Malgorzata Lenarcik; Teresa Klepacka; Irena Koch; Elzbieta Michalak; Katarzyna Szamotulska
Journal:  Tumour Biol       Date:  2016-05-20

Review 10.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.